Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-04-23
2008-09-16
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07425571
ABSTRACT:
The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
REFERENCES:
patent: 3819706 (1974-06-01), Mehta
patent: 3885046 (1975-05-01), Mehta
patent: 4089855 (1978-05-01), Chatterjie et al.
patent: 4172896 (1979-10-01), Uno et al.
patent: 4513006 (1985-04-01), Maryanoff et al.
patent: 4673679 (1987-06-01), Aungst et al.
patent: 4689332 (1987-08-01), McLaughin et al.
patent: 4855306 (1989-08-01), Markstein et al.
patent: 5312925 (1994-05-01), Allen et al.
patent: 5358970 (1994-10-01), Ruff et al.
patent: 5403595 (1995-04-01), Kitchell et al.
patent: 5426112 (1995-06-01), Zagon et al.
patent: 5427798 (1995-06-01), Ludwig et al.
patent: 5486362 (1996-01-01), Kitchell
patent: 5512593 (1996-04-01), Dante
patent: 5541231 (1996-07-01), Ruff et al.
patent: 5719197 (1998-02-01), Kanios et al.
patent: 5731000 (1998-03-01), Ruff et al.
patent: 5763493 (1998-06-01), Ruff et al.
patent: 5817665 (1998-10-01), Dante
patent: 5856332 (1999-01-01), Dante
patent: 5958962 (1999-09-01), Cook
patent: 6004970 (1999-12-01), O'Malley et al.
patent: 6034091 (2000-03-01), Dante
patent: 6071537 (2000-06-01), Shank
patent: 6071918 (2000-06-01), Cook
patent: 6110973 (2000-08-01), Young
patent: 6150366 (2000-11-01), Arenson et al.
patent: 6191117 (2001-02-01), Kozachuk
patent: 6197827 (2001-03-01), Cary
patent: 6210716 (2001-04-01), Chen et al.
patent: 6245766 (2001-06-01), Watsky
patent: 6248363 (2001-06-01), Patel et al.
patent: 6262049 (2001-07-01), Coffin et al.
patent: 6274579 (2001-08-01), Morgan et al.
patent: 6323236 (2001-11-01), McElroy
patent: 6344474 (2002-02-01), Maruani et al.
patent: 6437147 (2002-08-01), Andersen et al.
patent: 6441038 (2002-08-01), Loder et al.
patent: 6506799 (2003-01-01), Dasseux
patent: 6541478 (2003-04-01), O'Malley et al.
patent: 6548551 (2003-04-01), Hinz
patent: 6569449 (2003-05-01), Stinchcomb et al.
patent: 6686337 (2004-02-01), Connor
patent: 6713488 (2004-03-01), Sadee et al.
patent: 6905708 (2005-06-01), Li et al.
patent: 7109198 (2006-09-01), Gadde et al.
patent: 2001/0025038 (2001-09-01), Coffin et al.
patent: 2002/0025972 (2002-02-01), Hintz
patent: 2002/0037836 (2002-03-01), Henriksen
patent: 2002/0090615 (2002-07-01), Rosen et al.
patent: 2003/0055008 (2003-03-01), Marcotte
patent: 2003/0144174 (2003-07-01), Brenna et al.
patent: 2003/0144271 (2003-07-01), Shulman
patent: 2004/0002462 (2004-01-01), Najarian
patent: 2004/0029941 (2004-02-01), Jennings
patent: 2004/0033965 (2004-02-01), Gadde et al.
patent: 2004/0106576 (2004-06-01), Jerussi et al.
patent: 2004/0122033 (2004-06-01), Nargund et al.
patent: 2004/0198668 (2004-10-01), Gadde et al.
patent: 2004/0242974 (2004-12-01), Glover
patent: 2004/0254208 (2004-12-01), Weber et al.
patent: 2005/0026986 (2005-02-01), Maruani et al.
patent: 2005/0137144 (2005-06-01), Gadde et al.
patent: 2005/0143322 (2005-06-01), Gadde et al.
patent: 2005/0154002 (2005-07-01), Crooks et al.
patent: 2005/0181070 (2005-08-01), Gadde et al.
patent: 2005/0215552 (2005-09-01), Gadde et al.
patent: 2005/0277579 (2005-12-01), Krishnano et al.
patent: 2006/0009514 (2006-01-01), Gadde et al.
patent: 2006/0058293 (2006-03-01), Weber et al.
patent: 2006/0079501 (2006-04-01), Gadde et al.
patent: 2006/0100205 (2006-05-01), Weber et al.
patent: 2006/0142290 (2006-06-01), Weber et al.
patent: 2006/0160750 (2006-07-01), Gadde et al.
patent: 0 442 769 (1991-08-01), None
patent: 2214241 (1996-06-01), None
patent: WO 90/13294 (1990-11-01), None
patent: WO 96/09047 (1996-03-01), None
patent: WO 99/37305 (1999-07-01), None
patent: WO 00/50020 (2000-08-01), None
patent: WO 00/51548 (2000-09-01), None
patent: WO 00/76493 (2000-12-01), None
patent: WO 01/62257 (2001-08-01), None
patent: WO 02/09694 (2002-02-01), None
patent: WO 03/013524 (2003-02-01), None
patent: WO 03/092682 (2003-11-01), None
patent: WO 03/097046 (2003-11-01), None
patent: WO 03/097046 (2003-11-01), None
patent: WO 2004/009015 (2004-01-01), None
patent: WO 2004/024096 (2004-03-01), None
patent: WO 2004/050020 (2004-06-01), None
patent: WO 2004/096201 (2004-11-01), None
patent: WO 2004/110368 (2004-12-01), None
patent: WO 2004/110375 (2004-12-01), None
patent: WO 2005/000217 (2005-01-01), None
patent: WO 2005/049043 (2005-06-01), None
patent: WO 2006/017504 (2006-02-01), None
Ayala, “Weight Loss Associated With the Administration of Zonisamide”, AES Proceedings, Epilepsia 41(Suppl. 7) :99 (2000) -No. 2.041.
Gadde et al, “Zonisamide for Weight Loss in Obese Adults—A Randomized Controlled Trial”, JAMA 289(14) :1820-1825 (2003).
Gadde et al, “Bupropion for Weight Loss: An Investigation of Efficacy and Tolerability in Overweight and Obese Women”, Obesity Research 9(9) :544-551 (2001).
Gadde et al, “Randomized Controlled Trial of Zonisamide for Treating Obesity”, American Epilepsy Society, http://164.109.45.39/submission/aes/status/..\preview.full.asp?presid=2% 2E258, Sep. 11, 2002.
Gadde et al, “Randomized Trial of Weight Loss Efficacy of Zonisamide”, No. 304, 26(Suppl 1), Aug. 2002, International Journal of Obesity and Related Metabolic Disorders, Journal of the International Association for the Study of Obesity, Ninth International Congress on Obesity, Sao Paolo, Brazil, Aug. 24-29, 2002.
Gadde et al, “Zonisamide in Obesity: A 16-Week Randomized Trial”, No. NR473, New Research, American Psychiatric Association 2002 Annual Meeting, May 18-23, 2002, Philadelphia, Pennsylvania.
Gadde and Logue, “Bupropion Sustained Release in Obesity: A Randomized Double-Blind, Placebo-Controlled Study”, No. NR634, New Research Program & Abstracts, American Psychiatric Association, 1999 Annual Meeting, The Clinician, May 15-20, 1999, Washington, D.C.
Ginsberg and Sussman, “Effects of Mood Stabilizers on Weight”, Primary Psychiatry 7(5):49-58 (2000).
Grady, “Quest for Weight-Loss Drug Takes an Unusual Turn”, The New York Times—Health, www.nytimes.com, Mar. 15, 2003.
Kanios et al, “Compositions and methods for topical administration of pharmaceutically active agents”, Database USPT on West—USP 5,719,197, Feb. 17, 1998.
Matsuura, “Indication for Anterior Temporal Lobectomy in Patients with Temporal Lobe Epilepsy and Psychopathology”, Epilepsia 41(Suppl. 9) :39-42 (2000).
Morris, III, “The Effect of Zonisamide Administration on Patient Weight”, A Scientific Exhibit at the American Epilepsy Society Annual Meeting, Dec. 3, 2000, Los Angeles, California.
Walker et al, “Chronic Toxicity of the Anticonvulsant Zonisamide in Beagle Dogs”, Fundamental and Applied Toxicology 11:333-342 (1988).
Welty et al, “Weight Loss Associated With Use of Zonisamide in European and US Clinical Trials”, A Compendium of Posters and Platform Sessions for Zonegran®, Presented at the Annual Meeting 2001 of the American Epilepsy Society, Nov. 30-Dec. 5, 2001, Philadelphia, Pennsylvania.
Wilner, “Is Weight Loss With Zonisamide Gender-Specific?”, Dr. Tran, 2002 Annual Meeting of the American Epilepsy Society, https://secure.neurohub.net/cgi-perf/get.cgi?pub=52318&text=htm.
“A Novel Twist on Binge Eating Treatment” Primary Psychiatry; 6(10) 24-29 (1999).
Anderson, et al. Bupropion SR enhances weight loss Obesity R., vol. 10, N. 7, 2002, pp. 633-641, XP002351373.
Altman and Bland. “Standard Deviations and Standard Errors,” BMJ; 2005:331:903.
Appolinario et al. “Pharmacological Approaches in the Treatment of Binge Eating Disorder.” Current Drug Targets; 5:301-307 (2004).
Asconape. “Some Common Issues in the Use of Antiepileptic Drugs.” Seminars in Neurology; 22(1):27-39 (2002).
Atkinson, Clinical
Gadde Kishore M.
Krishnan K. Ranga R.
Henley, III Raymond J
Knobbe Martens Olson and Bear LLP
Orexigen Therapeutics, Inc.
LandOfFree
Method for treating obesity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating obesity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating obesity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3983187